Advertisement

Treatment of bleeding irregularities in women with copper-containing IUDs: a systematic review

      Abstract

      Background

      Bleeding irregularities, such as intermenstrual spotting or heavy or prolonged menstrual bleeding, are common among copper-containing intrauterine device (Cu-IUD) users and are one of the leading reasons for method discontinuation. This review evaluates the evidence for effective therapeutic and preventive treatments for bleeding irregularities during Cu-IUD use.

      Study Design

      We searched the PubMed database for peer-reviewed articles that were published in any language from inception of the database through March 2012 and were relevant to treatments for irregular bleeding during Cu-IUD use. We used standard abstract forms and grading systems to summarize and assess the quality of the evidence.

      Results

      From 1470 articles, we identified 17 articles that met our inclusion criteria. Evidence from two studies of poor quality demonstrated that antifibrinolytic agents or nonsteroidal anti-inflammatory drugs (NSAIDs) have been used for intermenstrual bleeding or spotting among a small number of Cu-IUD users with mixed results. Evidence from 10 studies of fair to poor quality suggested that some NSAIDs may significantly reduce menstrual blood loss or bleeding duration among Cu-IUD users with heavy or prolonged menstrual bleeding. Antifibrinolytic drugs or antidiuretics may also help reduce blood loss. High-dose aspirin was shown to increase blood loss among those with baseline menorrhagia. Evidence from five studies of fair to poor quality suggested that bleeding irregularities among new Cu-IUD users may be prevented with NSAIDs, although one large study of good quality suggested that prophylactic treatment with ibuprofen does not affect continuation of Cu-IUD use. Evidence from two studies of fair to poor quality suggested that antifibrinolytic agents might be helpful in preventing heavy or prolonged menstrual bleeding among new Cu-IUD users.

      Conclusions

      Limited evidence suggests that NSAIDs may be effective treatments for bleeding irregularities associated with Cu-IUD use; antifibrinolytic agents and antidiuretics have also been studied as possible treatments in a small number of subjects, but their safety has not been well documented. NSAIDs and antifibrinolytics may also prevent bleeding irregularities among new CU-IUD users. Preventive NSAID use, however, does not impact Cu-IUD continuation.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • d'Arcangues C.
        Worldwide use of intrauterine devices for contraception.
        Contraception. 2007; 75: S2-S7
        • Mosher W.D.
        • Jones J.
        Use of contraception in the United States: 1982���2008.
        Vital Health Stat. 2010; 23: 1-44
        • Sivin I.
        Utility and drawbacks of continuous use of a copper T IUD for 20 years.
        Contraception. 2007; 75: S70-S75
        • Kulier R.
        • O'Brien P.A.
        • Helmerhorst F.M.
        • Usher-Patel M.
        • D'Arcangues C.
        Copper containing, framed intra-uterine devices for contraception.
        Cochrane Database Syst Rev. 2007; : CD005347
        • Sivin I.
        • Stern J.
        • Diaz S.
        • et al.
        Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices.
        Am J Obstet Gynecol. 1992; 166: 1208-1213
        • Andrade A.T.
        • Pizarro E.
        • Shaw Jr., S.T.
        • et al.
        Consequences of uterine blood loss caused by various intrauterine contraceptive devices in South American women. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction.
        Contraception. 1988; 38: 1-18
        • Ylikorkala O.
        Prostaglandin synthesis inhibitors in menorrhagia, intrauterine contraceptive device-induced side effects and endometriosis.
        Pharmacol Toxicol. 1994; 75: 86-88
        • Grimes D.A.
        • Hubacher D.
        • Lopez L.M.
        • Schulz K.F.
        Non-steroidal anti-inflammatory drugs for heavy bleeding or pain associated with intrauterine-device use.
        Cochrane Database Syst Rev. 2006; : CD006034
        • World Health Organization
        Selected practice recommendations for contraception use. 2nd ed. WHO, Geneva2004
        • Newton J.
        • Barnard G.
        • Collins W.
        A rapid method for measuring menstrual blood loss using automatic extraction.
        Contraception. 1977; 16: 269-282
        • Higham J.M.
        • O'Brien P.M.
        • Shaw R.W.
        Assessment of menstrual blood loss using a pictorial chart.
        Br J Obstet Gynaecol. 1990; 97: 734-739
        • Mohllajee A.P.
        • Curtis K.M.
        • Flanagan R.G.
        • et al.
        Keeping up with evidence a new system for WHO's evidence-based family planning guidance.
        Am J Prev Med. 2005; 28: 483-490
        • Harris R.P.
        • Helfand M.
        • Woolf S.H.
        • et al.
        Current methods of the US Preventive Services Task Force: a review of the process.
        Am J Prev Med. 2001; 20: 21-35
        • Pizarro E.
        • Mehech G.
        • Hidalgo M.
        • Munoz G.
        • Romero C.
        Effect of meclofenamic acid on menstruation in hypermenorrheic women using intrauterine devices.
        Rev Chil Obstet Ginecol. 1988; 53: 43-56
        • Pedron N.
        • Lozano M.
        • Aznar R.
        Treatment of hypermenorrhea with mefenamic acid in women using IUDs.
        Contracept Deliv Syst. 1982; 3: 135-139
        • Blum M.
        • Pery J.
        Prevention of iron deficiency anemia in IUD users by prostaglandin synthetase inhibitors.
        Contracept Deliv Syst. 1984; 5: 21-23
        • Tauber P.F.
        • Wolf A.S.
        • Herting W.
        • Zaneveld L.J.
        Hemorrhage induced by intrauterine devices: control by local proteinase inhibition.
        Fertil Steril. 1977; 28: 1375-1377
        • Toppozada M.
        • Anwar M.
        • Abdel Rahman H.
        • Gaweesh S.
        Control of IUD-induced bleeding by three non-steroidal anti-inflammatory drugs.
        Contracept Deliv Syst. 1982; 3: 117-125
        • Di Lieto A.
        • Catalano D.
        • Miranda L.
        • Paladini A.
        Action of a prostaglandin synthetase inhibitor on IUD associated uterine bleeding.
        Clin Exp Obstet Gynecol. 1987; 14: 41-44
        • Toppozada M.
        • El-Attar A.
        • El-Ayyat M.A.
        • Khamis Y.
        Management of uterine bleeding by PGs or their synthesis inhibitors.
        Adv Prostaglandin Thromboxane Res. 1980; 8: 1459-1463
      1. Chinese National IUD Research Working Group. [Prevention and treatment of IUD-induced menorrhagia with antifibrinolytic and antiprostaglandin drugs]. Zhonghua Fu Chan Ke Za Zhi 1987;22:291-4,3

        • Mercorio F.
        • De Simone R.
        • Di Carlo C.
        • et al.
        Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device-related menorrhagia: a pilot study.
        Hum Reprod. 2003; 18: 2319-2322
        • Wu S.
        • Wang C.
        • Cheng W.
        • et al.
        Randomized multi-center study of baofuxin for treatment of bleeding side-effect induced by IUD.
        Reprod Contracep. 2000; 11: 152-157
        • Ylikorkala O.
        • Viinikka L.
        Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices.
        Br J Obstet Gynaecol. 1983; 90: 78-83
        • Pedron N.
        • Lozano M.
        • Gallegos A.J.
        The effect of acetylsalicylic acid on menstrual blood loss in women with IUDs.
        Contraception. 1987; 36: 295-303
        • Hubacher D.
        • Reyes V.
        • Lillo S.
        • et al.
        Preventing copper intrauterine device removals due to side effects among first-time users: randomized trial to study the effect of prophylactic ibuprofen.
        Hum Reprod. 2006; 21: 1467-1472
        • Makarainen L.
        • Ylikorkala O.
        Ibuprofen prevents IUCD-induced increases in menstrual blood loss.
        Br J Obstet Gynaecol. 1986; 93: 285-288
        • Roy S.
        • Shaw Jr., S.T.
        Role of prostaglandins in IUD-associated uterine bleeding ��� effect of a prostaglandin synthetase inhibitor (ibuprofen).
        Obstet Gynecol. 1981; 58: 101-106
        • Ylikorkala O.
        • Kauppila A.
        • Siljander M.
        Anti-prostglandin therapy in prevention of side-effects of intrauterine contraceptive devices.
        Lancet. 1978; 2: 393-395
        • Lin X.
        • Gao E.S.
        • Li D.
        • et al.
        Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women.
        Acta Obstet Gynecol Scand. 2007; 86: 1126-1129
      2. UBM Medica. Transamin ��� detailed prescribing information. 2011. Available at: http://www.mims.com.vn/Malaysia/drug/info/Transamin/?type=full#Manufacturer [Last accessed March 27, 2012].

      3. World Health Organization. WHO model list of essential medicines, 17th list. 2011. Available at: http://whqlibdoc.who.int/hq/2011/a95053_eng.pdf [Last accessed March 27, 2012].

        • Food and Drug Administration
        Lysteda (tranexamic acid) tables: highlights of prescribing information.
        (Available at, [Last accessed March 27, 2012])
        • Henry D.
        • Carless P.
        • Fergusson D.
        • Laupacis A.
        The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.
        CMAJ. 2009; 180: 183-193
        • Lethaby A.
        • Augood C.
        • Duckitt K.
        • Farquhar C.
        Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding.
        Cochrane Database Syst Rev. 2007; : CD000400
        • Edlund M.
        Nonhormonal treatments for heavy menstrual bleeding.
        J Womens Health (Larchmt). 2011; 20: 1645-1653